Immunocore
Inventor of the ImmTAC soluble TCR bispecific; tebentafusp was the first to improve survival in a solid tumour.
Tebentafusp (Kimmtrak), brenetafusp (PRAME, phase 3 PRISM-MEL-301 in melanoma), IMC-R117C (PIWIL1, colorectal).
The first drug to improve survival in metastatic uveal melanoma, and the first TCR-based bispecific.
Tebentafusp's successor: a soluble T-cell receptor that recognises a fragment of PRAME, a protein present in most melanomas and many other cancers, and drags T cells onto the tumour.
Pages like this
not linked directly; found by shared links- Targetgp100 (PMEL)
Shares IMCgp100-202, Oxford Cancer – Oxford University Hospitals and University of Oxford, Tebentafusp, Uveal melanoma.
- IdeaTCR therapeutics for non-HLA-A*02 patients
Shares Brenetafusp, Tebentafusp, PRAME, Melanoma.
- TermHLA-A*02:01 restriction
Shares Brenetafusp, Tebentafusp, PRAME, Uveal melanoma.
- CompanyImmatics
Shares Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, PRAME, Melanoma.
- TargetCD3
Shares IMCgp100-202, PRISM-MEL-301, Brenetafusp, Tebentafusp.
- CollectionMelanoma Research Alliance (MRA)
Shares Uveal melanoma, Melanoma.
- TechnologyPercutaneous hepatic perfusion (chemosaturation)
Shares Tebentafusp, Uveal melanoma.
- TechnologyT-cell engagers (bispecific)
Shares IMCgp100-202, PRISM-MEL-301, Brenetafusp, Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface.